The bioinformatics industry in Benelux is a burgeoning field focused on utilizing technology and data analysis to enhance biotechnology and healthcare. Companies in this sector develop software and tools that aid in understanding biological data, particularly genomic sequences, and they contribute significantly to personalized medicine and drug discovery. With a mix of startups and established firms, the market is increasingly exploring artificial intelligence and machine learning to improve analysis and diagnostic capabilities. As the demand for innovative healthcare solutions grows, Benelux is becoming a hub for investment, scientific collaboration, and breakthrough bioinformatics applications.


Among the top bioinformatics investors in Benelux, venture capital firms dominate the scene, highlighting the region's focus on innovation. Based in vibrant cities like Amsterdam and Brussels, these investors range from small firms to larger entities, typically employing 1 to 500 staff members. Founded from the mid-1980s to the mid-2010s, they collectively engaged in a notable number of deals in 2024, confirming their commitment to advancing the biotech sector. From seed funding to substantial venture rounds, these investors play a crucial role in shaping the future of bioinformatics.


Top 19 Bioinformatics Investors in Benelux


1. European Innovation Council (EIC)


The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, the EIC offers various funding programs, including the EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale their technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, the EIC has been involved in significant transactions within the bioinformatics space, such as Sequentia Biotech, which raised over $11 million in Series A funding in 2024, and Scipio Bioscience, which secured $2.35 million through a convertible note in 2023. Additionally, the EIC has provided grants to companies like Sequentia Biotech and enGenome, further emphasizing its commitment to supporting innovation in the bioinformatics sector.


2. M Ventures

  • Website: m-ventures.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 2009
  • Headcount: 11-50
  • Number of deals in 2024: 18
  • LinkedIn: merck-ventures

M Ventures is a venture capital fund based in Amsterdam, Netherlands, founded in 2009. The firm specializes in investing in transformative ideas within the biotechnology and technology sectors, with a strong emphasis on healthcare, life sciences, and advanced technology. M Ventures collaborates closely with entrepreneurs to drive innovation and growth in their portfolio companies by providing funding and strategic guidance. Notably, M Ventures has been involved in several significant transactions in the bioinformatics space, including a Series C investment of $165 million in DNA Script, a company focused on DNA synthesis technology, and a recent venture round investment of $14 million in Nucleai, which specializes in AI-driven pathology solutions. Additionally, they participated in a Series A funding round for Scipio Bioscience, further demonstrating their commitment to supporting innovative companies in the bioinformatics and biotechnology sectors.


3. Life Sciences Partners (LSP)

  • Website: lspvc.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 1987
  • Headcount: 11-50
  • Number of deals in 2024: 15
  • LinkedIn: lsp-bioventures

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, Netherlands, founded in 1987. The firm specializes in private equity investments within the healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on fostering advancements in healthcare that address unmet medical needs, particularly in drug development and medical technology. Notably, LSP has been involved in significant transactions in the bioinformatics context, such as their investments in DNA Script, which raised substantial funding across multiple rounds (Series B and C) totaling over $250 million. DNA Script is known for its innovative DNA synthesis technology, which is highly relevant to bioinformatics applications. Additionally, LSP's investment in Seahorse Bioscience and PamGene further demonstrates their commitment to supporting companies that contribute to advancements in life sciences, including bioinformatics.


4. Forbion

  • Website: forbion.com
  • Type: Venture Capital
  • Headquarters: Naarden, North Holland, Netherlands
  • Founded year: 2006
  • Headcount: 11-50
  • Number of deals in 2024: 23
  • LinkedIn: forbion-capital-partners

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, Netherlands. The firm specializes in the life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notably, Forbion has been involved in significant transactions in the bioinformatics context, such as leading investments in Capstan Therapeutics, which focuses on CAR-T therapies for autoimmune disorders, and VectorY Therapeutics, which is developing vectorized antibody therapies for neurodegenerative diseases. These investments highlight Forbion's commitment to advancing innovative therapies that rely on bioinformatics for their development and application.


5. European Investment Bank (EIB)


The European Investment Bank (EIB) is a public entity based in Luxembourg that provides a range of financial services, including loans, equity investments, guarantees, and advisory services, aimed at supporting sustainable projects across various sectors. Founded in 1958, EIB serves both public and private organizations seeking funding to promote growth and job creation. In the context of bioinformatics, EIB has been involved in several notable transactions, including a €40 million credit facility to Cellectis to support its research, development, and innovation activities, as well as multiple debt financing rounds for Evotec, a company focused on drug discovery and development. These transactions highlight EIB's active role in financing initiatives that are crucial for advancements in the bioinformatics industry.


6. Gilde Healthcare


Gilde Healthcare is a venture capital firm based in Utrecht, Netherlands, specializing in healthcare investments. Founded in 1982, the firm manages over €2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and therapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notably, they have acquired a majority stake in Viroclinics Biosciences, a company that may engage in bioinformatics-related research and services. Additionally, Gilde has participated in funding rounds for Agendia, a company that focuses on molecular diagnostics and personalized medicine, which are areas that heavily rely on bioinformatics. Their diverse portfolio and strategic support for healthcare businesses position them as a significant player in the healthcare investment landscape, including sectors relevant to bioinformatics.


7. BGV (BioGeneration Ventures)


BGV (BioGeneration Ventures) is a venture capital firm based in Naarden, North Holland, Netherlands, specializing in seed investments in innovative early-stage biotech companies. Founded in 2006, BGV focuses on providing funding and support to help these companies develop disruptive solutions for unmet medical needs. Their portfolio includes various biotech firms that are advancing healthcare solutions. Notably, BGV has participated in significant transactions such as Panome Bio, a company specializing in metabolomics and proteomics services, which are critical areas within bioinformatics. They also invested in VectorY Therapeutics, which is working on vectorized antibody therapies for neurodegenerative diseases, further showcasing their engagement in the life sciences sector that often intersects with bioinformatics. Their investment in River BioMedics, which raised funds in a seed round, also reflects their commitment to supporting early-stage companies in the biotech field.


8. Qiagen

  • Website: qiagen.com
  • Type: Corporate
  • Headquarters: Venlo, Limburg, Netherlands
  • Founded year: 1986
  • Headcount: 5001-10000
  • LinkedIn: qiagen

QIAGEN N.V. is a biotechnology company based in Venlo, Limburg, Netherlands, specializing in sample and assay technologies for molecular diagnostics, applied testing, and research. Founded in 1986, Qiagen has established itself as a global leader in providing essential tools for accurate analysis and research in the healthcare and academic sectors. Notably, Qiagen has made significant investments in the bioinformatics field through strategic acquisitions. In 2013, Qiagen acquired Ingenuity Systems, a US-based genomic data analysis company, for $105 million, aiming to enhance its curated database and improve genomic data interpretation. That same year, Qiagen also acquired CLC bio, a company specializing in bioinformatics solutions, further expanding its capabilities in this area. In 2019, Qiagen continued its growth in bioinformatics by acquiring N-of-One, a company focused on precision medicine and genomic data interpretation. These transactions highlight Qiagen's commitment to integrating bioinformatics into its product offerings and enhancing its genomics portfolio.


9. Noshaq

  • Website: noshaq.be
  • Type: Venture Capital
  • Headquarters: Belgium
  • Founded year: 1985
  • Headcount: 11-50
  • Number of deals in 2024: 11
  • LinkedIn: noshaq-be

Noshaq is a venture capital investment fund based in Belgium, founded in 1985, that provides financial solutions and strategic support to small and medium-sized enterprises (SMEs) in the province of Liège. The firm focuses on funding, project structuring, and business development, particularly in sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has been involved in several transactions relevant to the bioinformatics field, including: 1) LiveDrop, a ULiège spin-off that raised €2.3 million to commercialize a high-tech instrument for sorting biological cells, indicating a focus on innovative biological technologies. 2) THERAtRAME SA, which closed a financing round of €4.5 million to develop new therapeutics targeting tRNA epitranscriptomics in cancer, showcasing their commitment to advancing healthcare solutions. 3) Radiomics, which secured €6 million for projects related to imaging AI solutions for lung cancer, further emphasizing their investment in bioinformatics and related technologies. These transactions highlight Noshaq's active role in supporting advancements in the biotech and bioinformatics sectors.


10. Droia Ventures

  • Website: droiaventures.com
  • Type: Venture Capital
  • Headquarters: Zaventem, Flanders, Belgium
  • Founded year: 2011
  • Headcount: 11-50
  • Number of deals in 2024: 5
  • LinkedIn: droiaventures

Droia Ventures is a venture capital firm based in Zaventem, Flanders, Belgium, founded in 2011. The firm specializes in the life sciences sector, focusing on investments in drug development companies. They provide support for clinical proof of concept and scientific validation of innovative therapies, primarily targeting oncology and genetic diseases. Their clientele consists of biotechnology firms seeking funding and expertise to advance their therapeutic innovations. Notably, Droia Ventures has been involved in significant transactions such as the Series C funding of Frontier Medicines, which raised $80 million in February 2024 to advance its precision oncology pipeline. Additionally, they participated in earlier funding rounds for Frontier Medicines, including a Series B round that raised $88.5 million in July 2021 and a Series A round of $67 million in June 2019. These investments highlight Droia Ventures' commitment to supporting companies that are at the forefront of integrating bioinformatics into drug development and precision medicine.


11. Gimv

  • Website: gimv.com
  • Type: Venture Capital
  • Headquarters: Antwerp, Flanders, Belgium
  • Founded year: 1980
  • Headcount: 51-200
  • Number of deals in 2024: 8
  • LinkedIn: gimv

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Notably, Gimv has been involved in several transactions relevant to the bioinformatics sector, such as their investments in PamGene, which raised funds in both Series A and Series B rounds, focusing on genomic and proteomic technologies. Additionally, Gimv co-led a Series A financing round for Anjarium Biosciences, which raised CHF 55.5 million to advance its therapeutic pipeline, indicating their commitment to supporting bioinformatics and biotechnology innovations. These transactions highlight Gimv's active role in the bioinformatics industry, making them a significant player in this space.


12. V-Bio Ventures

  • Website: v-bio.ventures
  • Type: Venture Capital
  • Headquarters: Ghent, Flanders, Belgium
  • Founded year: 2015
  • Headcount: 1-10
  • Number of deals in 2024: 6
  • LinkedIn: v-bio-ventures

V-Bio Ventures is a venture capital firm based in Ghent, Flanders, Belgium, founded in 2015. The firm specializes in life sciences investments, focusing on innovative companies in therapeutics, diagnostics, and sustainable agriculture. V-Bio Ventures aims to transform scientific innovations into impactful products that address unmet needs in healthcare and agriculture. Notable transactions include leading a €23 million Series A financing round for Sibylla Biotech, which is advancing its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) approach, and participating in funding rounds for Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals. These investments highlight V-Bio Ventures' commitment to supporting companies that leverage advanced scientific techniques, including those relevant to bioinformatics, to drive innovation in healthcare.


13. Thuja Capital

  • Website: thujacapital.com
  • Type: Venture Capital
  • Headquarters: Utrecht, Utrecht, Netherlands
  • Founded year: 2006
  • Headcount: 1-10
  • Number of deals in 2024: 3
  • LinkedIn: thuja-capital

Thuja Capital Management BV is a venture capital firm based in Utrecht, Netherlands, founded in 2006. The firm specializes in healthcare investments, focusing on supporting innovative healthcare ventures from start-up to scale-up. Thuja Capital provides funding and strategic guidance to companies in the biotech and medtech sectors. Notable transactions include their participation in the $8M Series A financing round for InnoSIGN, which aims to implement growth plans including clinical validation studies, and their investment in Cristal Therapeutics, which raised approximately $7.5 million for developing novel therapies. Their recent investment in Tacalyx, which raised over $7.5 million in a seed round, further emphasizes their commitment to advancing healthcare innovations. These transactions highlight Thuja Capital's active role in the healthcare sector, including areas that overlap with bioinformatics.


14. Pmv

  • Website: pmv.eu
  • Type: Venture Capital
  • Headquarters: Brussels, Brussels, Belgium
  • Founded year: 2001
  • Headcount: 51-200
  • Number of deals in 2024: 11
  • LinkedIn: pmv-eu

Participatiemaatschappij Vlaanderen (PMV) is a public investment company based in Brussels, Belgium, founded in 2001. It provides a variety of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across multiple sectors, including life sciences. PMV has been involved in several notable transactions in the bioinformatics and life sciences fields. For instance, it participated in funding rounds for PharmaFluidics, a research diagnostics spinout from Vrije Universiteit Brussel, which focuses on innovative diagnostic solutions. PMV also invested in eTheRNA, a company specializing in immunotherapies, which raised €39M in a Series B2 financing round. These investments highlight PMV's commitment to supporting companies that are advancing technologies relevant to bioinformatics and life sciences.


15. Eurofins

  • Website: eurofins.com
  • Type: Corporate
  • Headquarters: Luxembourg
  • Founded year: 1987
  • Headcount: 10001+
  • Number of deals in 2024: 8
  • LinkedIn: eurofins

Eurofins Scientific SE is a prominent laboratory testing company based in Luxembourg, founded in 1987. It provides a comprehensive range of analytical and testing services across various industries, including pharmaceuticals, food, and environmental sectors. With over 900 laboratories in 62 countries, Eurofins has a significant global presence and expertise in testing and diagnostics. Notably, Eurofins has made several strategic acquisitions that bolster its capabilities in the bioinformatics domain. For instance, the acquisition of Genetic Lab in December 2021 enhances their presence in molecular biology-based testing for diagnostics and drug discovery. Similarly, the acquisition of AROS Applied Biotechnology in February 2013 further strengthens their portfolio in biotechnology services. These transactions reflect Eurofins' commitment to expanding its role in the bioinformatics sector, particularly in clinical diagnostics and biomarker development.


16. Vesalius Biocapital Arkiv


Vesalius Biocapital Partners Sàrl is a venture capital firm based in Woluwe-Saint-Pierre, Brussels, Belgium, founded in 2007. The firm specializes in providing funding and strategic support to innovative life science companies across Europe. With a focus on therapeutics, medical devices, and diagnostics, Vesalius Biocapital assists startups with capital, business optimization, and connections to industry leaders. Notably, they led a €19 million Series B financing round for OncoDNA, a company that develops software for cancer diagnostics, highlighting their engagement in the bioinformatics sector. Additionally, they participated in funding rounds for Ncardia, a stem cell technology company involved in cardiovascular drug discovery, which also intersects with bioinformatics through its focus on high throughput screening and safety assays. Their diverse portfolio reflects a commitment to advancing life sciences, including areas relevant to bioinformatics.


17. 3B Future Health Fund I & II


3B Future Health Fund I & II is a venture capital firm based in Luxembourg, founded in 2016, that focuses on investing in early-stage healthcare companies, particularly in oncology and rare diseases. The firm aims to improve patient outcomes through transformative treatments by providing financial support and strategic management to its portfolio companies. Notable transactions include their participation in the Series A funding for Sibylla Biotech, which is developing innovative pharmacological approaches, and their investment in Geneos Therapeutics, which is advancing cancer therapies. Their involvement in Fore Biotherapeutics, a precision oncology startup, further highlights their commitment to supporting companies that are likely to leverage bioinformatics in their research and development processes.


18. Inkef

  • Website: inkef.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 2010
  • Headcount: 11-50
  • Number of deals in 2024: 4
  • LinkedIn: inkef-netherlands-manager

Inkef is a venture capital firm based in Amsterdam, Netherlands, founded in 2010. The firm specializes in early-stage investments primarily in the healthcare and technology sectors, focusing on mission-driven entrepreneurs. Inkef provides not only funding but also strategic guidance to help scale businesses, emphasizing long-term value creation. Notably, Inkef has participated in significant funding rounds for companies in the bioinformatics and biotechnology fields. For instance, they co-led an €80 million Series B investment in Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals for oncology. Additionally, they invested in Anavo Therapeutics, contributing to their Seed funding rounds, which total €28 million. Inkef also supported Scenic Biotech, a therapeutics company that raised funds to develop genetic off-switches for cancer and rare genetic diseases. These transactions highlight Inkef's commitment to advancing innovations in the life sciences, making them a relevant player in the bioinformatics investment landscape.


19. Brabantse Ontwikkelings Maatschappij (BOM)


The Brabantse Ontwikkelings Maatschappij (BOM) is a venture capital firm based in Tilburg, North Brabant, Netherlands, founded in 1983. BOM acts as a development agency that supports startups and scale-ups in the Brabant region, offering various programs aimed at enhancing business growth, including readiness programs for venture capital and innovation in sustainable food and energy sectors. BOM collaborates with businesses to provide funding, expertise, and networking opportunities, facilitating their success in competitive markets. Among its notable transactions, BOM invested in ENPICOM, which raised $1,357,620 in a Series A round in March 2019, focusing on bioinformatics solutions. Additionally, BOM contributed to Cristal Therapeutics, which raised €12.8 million for the development of its innovative nanotech platform, relevant to the healthcare sector. BOM also participated in funding rounds for RiboPro, a company involved in biotechnology, further emphasizing its engagement in sectors that intersect with bioinformatics.



Bioinformatics Insights: Key Investors in Benelux


InvestorHeadquarterSizeFoundedDeals 2024
European Innovation Council (EIC)Brussels, Brussels, Belgium201-500195857
M VenturesAmsterdam, North Holland, Netherlands11-50200918
Life Sciences Partners (LSP)Amsterdam, North Holland, Netherlands11-50198715
ForbionNaarden, North Holland, Netherlands11-50200623
European Investment Bank (EIB)Luxembourg1001-5000195899
Gilde HealthcareUtrecht, Utrecht, Netherlands51-200198212
BGV (BioGeneration Ventures)Naarden, North Holland, Netherlands1-1020066
QiagenVenlo, Limburg, Netherlands5001-1000019860
NoshaqBelgium11-50198511
Droia VenturesZaventem, Flanders, Belgium11-5020115
GimvAntwerp, Flanders, Belgium51-20019808
V-Bio VenturesGhent, Flanders, Belgium1-1020156
Thuja CapitalUtrecht, Utrecht, Netherlands1-1020063
PmvBrussels, Brussels, Belgium51-200200111
EurofinsLuxembourg10001+19878
Vesalius Biocapital ArkivWoluwe-Saint-Pierre, Brussels, Belgium1-1020078
3B Future Health Fund I & IILuxembourg11-5020163
InkefAmsterdam, North Holland, Netherlands11-5020104
Brabantse Ontwikkelings Maatschappij (BOM)Tilburg, North Brabant, Netherlands51-200198310


Want to find more investors focusing on the bioinformatics industry?

If you want to find more investors that are active in the bioinformaticsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!